Prix bas
CHF169.60
Pas encore paru. Cet article sera disponible le 01.03.2025
Auteur
Professor Dame Anna Dominiczak DBE, MD, FRCP, FAHA, FRSE, FMedSci is Regius Professor of Medicine at the University of Glasgow; Honorary Consultant Physician and Endocrinologist at NHS Greater Glasgow and Clyde; and Health Innovation Champion for the Medical Research Council. In 2016, she was awarded a DBE for services to cardiovascular and medical science. Dominiczak is currently seconded to the Department of Health and Social Care in the UK Government as Director of Laboratories, NHS Test & Trace. In 2020, she successfully led the Lighthouse Laboratory in Glasgow (LLiG), leading to her current role where she continues to expand the Lighthouse laboratory network. She is accountable for the UK labs testing capability across a coordinated network of 13 labs. As the network continues to evolve, Professor Dominiczak's focus remains on delivering a triple helix partnership between academia, the NHS and industry to transform the long-term testing capability of the UK for COVID and beyond.
Dr. Sandosh Padmanabhan MD, PhD, FRCP, FAHA, FBHS, FBPhS is a Professor and Physician at the Institute of Cardiovascular and Medical Sciences, University of Glasgow. Dr. Padmanabhan completed his MBBS and MD at JIPMER, Pondicherry, India and was awarded the Gold Medal for MD General Medicine in 1995. His PhD thesis (1999-2003) on G-protein signaling in hypertension was awarded the Bellahouston Medal by the University of Glasgow in 2004, and he received the Austin Doyle Award from the International Society of Hypertension in 2004. Dr. Padmanabhan's pharmacogenetic genome-wide linkage study led to a BHF Intermediate Fellowship (2006-2009), and he also led a genome wide association analysis of hypertension between 2008 and 2010, resulting in the discovery of a new gene and pathway for hypertension. Dr. Padmanabhan was a visiting fellow to the Broad Institute of Harvard and MIT (2010-2012). Currently, he is a Fellow of the Royal College of Physicians, the British Hypertension Society, and the American Heart Association. His active research areas span the genetics of cardiovascular traits, pharmacogenomics and stratified medicine, and hypertension epidemiology.Dr Clugston is Dean of Corporate Engagement & Innovation and Chief Operating Officer of the College of Medical, Veterinary and Life Sciences. As Dean she leads the College's Innovation, Engagement and Enterprise Strategy. She is Director and SRO of the 'Living Laboratory for Precision Medicine'. The Living Laboratory is rapidly developing a life sciences industry ecosystem around the Queen Elizabeth University Hospital. The Living Laboratory has increased cross-sector collaboration and is turning research into treatments and innovations that benefit patients whilst making savings for the NHS locally and across Scotland. Dr Clugston was awarded the Lord Provost's Award from the City of Glasgow in 2017, in the category of health. She was also the 2018 recipient of the 30% Club Scholarship to the London Business School's Senior Executive Program. Dr Clugston is a Trustee of Glasgow Science Centre, and Board member of Precision Medicine Scotland.
Texte du rabat
The Living Laboratory for Precision Medicine: Solutions for Clinical Implementation provides a comprehensive resource on precision medicine through a convergence of innovation and solutions across multiple domains, including large population cohorts, artificial intelligence, genomics, phenomics, clinical trials, health economics and regulation exemplified by the living lab concept. This book is the first to look at precision medicine through the lens of last-mile solutions which make it broad in scope, practically relevant, and cutting-edge. The book explores the use of precision medicine to stimulate regional economic growth through a healthier population, savings on healthcare, and using innovation as a driver of economic development.
The term precision medicine has been popularized by clinical, scientific, political, financial and technological interests as the biggest innovation to revolutionize healthcare. While over the past decade a few precision medicine-based solutions have come to fruition, the transformative leap in healthcare delivery and population benefit is yet to be realized. Current focus on precision medicine primarily focuses on patient stratification which constrains it to either a single disease area, a few sub-disciplines, or using a limited set of genomic technologies. While useful, experience over the last few years indicates precision medicine needs to be considered as a complex process with multiple feedback loops requiring significant interdisciplinary collaboration and innovation.
Contenu